Sinomed enrolls patients to test BuMA Supreme Coronary Drug-Eluting Stent

Sinomed has completed enrollment in the PIONEER III randomized, controlled clinical trial testing the BuMA Supreme DES and support U.S. and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.

“BuMA Supreme brings an interesting new concept to drug-eluting stents with eG Coating™ technology and unique pharmacokinetics that targets a faster return of functional healing,” said Martin B. Leon, MD, Columbia UniversityMedical Center, USA, and Chairman of the Executive Committee of the PIONEER III study. “This earlier restoration can lead to safer long-term results by possibly reducing late stent thrombosis and neo-atherosclerosis,” Leon said in the press release.

“Noting Sionomed is the the first Chinese stent company to take on such an ambitious trial, Jianhua Sun, Chief Executive Officer, said: “BuMA Supreme is just one piece of our overall drug-eluting platform strategy and we are heavily investing in clinical trials to show the long-term benefits of this device while continuing our development of future generations.”